A strategy for developing new treatment paradigms for neuropsychiatric and neurocognitive symptoms in Alzheimer’s disease

Successful disease modifying drug development for Alzheimer’s disease (AD) has hit a roadblock with the recent failures of amyloid-based therapies, highlighting the translational disconnect between preclinical animal models and clinical outcome. Although disease modifying therapies are the Holy Grai...

Descripción completa

Detalles Bibliográficos
Autores principales: Geerts, Hugo, Roberts, Patrick, Spiros, Athan, Carr, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2013
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3627142/
https://www.ncbi.nlm.nih.gov/pubmed/23596419
http://dx.doi.org/10.3389/fphar.2013.00047

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3627142/
https://www.ncbi.nlm.nih.gov/pubmed/23596419
http://dx.doi.org/10.3389/fphar.2013.00047

Ejemplares similares